At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09995 REMEGEN
Closed Good Friday 04-02 16:08:21
115.200
+4.800
+4.35%
High116.500Low107.900Vol9.03M
Open113.000D1 Closing110.400Amplitude7.79%
Mkt Cap64.93BTradable Cap24.03BTotal Shares563.61M
T/O1.02BT/O Rate4.33%Tradable Shares208.58M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026
Stock News  ·  43 minutes ago
China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026
China International Capital Corporation Maintains Outperform Rating on REMEGEN, Raises Target Price to HK$133.7
Stock News  ·  45 minutes ago
China International Capital Corporation Maintains Outperform Rating on REMEGEN, Raises Target Price to HK$133.7
Lilly's Oral GLP-1 Weight Loss Drug Receives FDA Approval, Offering Daily Pill Alternative to Injections
Deep News  ·  52 minutes ago
Lilly's Oral GLP-1 Weight Loss Drug Receives FDA Approval, Offering Daily Pill Alternative to Injections
RemeGen (SEHK:9995) Is Up 30.0% After New HER2-Low Breast Cancer Approval Has The Bull Case Changed?
Simply Wall St.  ·  06:37
RemeGen (SEHK:9995) Is Up 30.0% After New HER2-Low Breast Cancer Approval Has The Bull Case Changed?
RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial
MT Newswires Live  ·  04-02 11:14
RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial
Stock Track | RemeGen Soars 5.07% Intraday Following NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288
Stock Track  ·  04-02 10:45
Stock Track | RemeGen Soars 5.07% Intraday Following NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288
RemeGen secures NMPA green light for Phase I/IIa trial of bispecific ADC RC288 targeting PSMA/B7H3
Bulletin Express  ·  04-01 22:44
RemeGen secures NMPA green light for Phase I/IIa trial of bispecific ADC RC288 targeting PSMA/B7H3
Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288
Stock News  ·  04-01 16:50
Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288
RemeGen Returns to Profitability in 2025; Shares Jump 6%
MT Newswires Live  ·  03-30
RemeGen Returns to Profitability in 2025; Shares Jump 6%
Insilico Medicine Soars 15% After Announcing $2.75 Billion Partnership with Eli Lilly
Deep News  ·  03-30
Insilico Medicine Soars 15% After Announcing $2.75 Billion Partnership with Eli Lilly
Stock Track | REMEGEN Soars 10.04% Intraday on Strong Annual Results and Profit Turnaround
Stock Track  ·  03-30
Stock Track | REMEGEN Soars 10.04% Intraday on Strong Annual Results and Profit Turnaround
REMEGEN Shares Surge Over 8% Following Strong Annual Results Showing Profit Turnaround
Stock News  ·  03-30
REMEGEN Shares Surge Over 8% Following Strong Annual Results Showing Profit Turnaround
Compensation Data Revealed for 68 Pharmaceutical Firms
Deep News  ·  03-28
Compensation Data Revealed for 68 Pharmaceutical Firms
Remegen Co.,Ltd. Board Approves Multiple Proposals Including the 2025 General Manager Work Report
Deep News  ·  03-27
Remegen Co.,Ltd. Board Approves Multiple Proposals Including the 2025 General Manager Work Report
REMEGEN Reports Annual Profit of 710 Million Yuan, Turning Around from Prior Year Loss
Stock News  ·  03-27
REMEGEN Reports Annual Profit of 710 Million Yuan, Turning Around from Prior Year Loss
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
Tiger Newspress  ·  03-27
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
Tiger Newspress  ·  03-26
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
REMEGEN Shares Climb Over 5% as Disitamab Vedotin Gains Fourth Indication Approval
Deep News  ·  03-24
REMEGEN Shares Climb Over 5% as Disitamab Vedotin Gains Fourth Indication Approval
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Tiger Newspress  ·  03-24
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Remegen's ADC Therapy Disitamab Vedotin Secures Approval for New Breast Cancer Indication
Stock News  ·  03-23
Remegen's ADC Therapy Disitamab Vedotin Secures Approval for New Breast Cancer Indication
No data available

Introduction

Company Name.
REMEGEN
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.
Issue price:
--